At Medeloop, our mission is to empower clinical researchers and healthcare teams with AI tools to generate evidence more efficiently, thoroughly, and productively.
We are building an operating system for clinical research, spanning the full research lifecycle: from grant discovery and funding, to real-world evidence generation from patient data, to delivering actionable intelligence at the point of care.
Rene Caissie
Co-Founder & CEO
Josh Walonoski
Co-Founder & CRCO
Anand Hirekatur
CTO
John Ayers
Chief Strategy Officer
Lauren Green
Chief of Staff
Mike Hao
GTM Strategy Lead
Tanishq Bhalla
VP of Product
Yorick Chern
VP of AI
Leaders in clinical research, biomedical informatics, health policy, and medical publishing, helping shape how Medeloop approaches evidence, validation, and clinical impact.
Former Editor-in-Chief of JAMA and the JAMA Network; Professor of Pediatrics and Public Health at Boston University. One of the most influential voices in clinical evidence, peer review, and medical publishing.
Department Chair of Critical Care Medicine at UPMC. World-renowned leader in critical care, clinical trials, and academic health systems.
Inaugural Director of the Data Science and AI Institute and professor at Johns Hopkins. Leading expert in NLP and ML applied to public health and clinical data.
Inaugural Clinical Research Information Officer and professor at UC San Diego. Nationally recognized leader in biomedical informatics and digital health.
Managing Director at Brookfield Private Equity. Former CEO of MediSolution, President of TELUS Health, Chairman of TELUS Global Ventures, and CEO of Intelerad.
Former U.S. FDA Commissioner and CMS Administrator. Currently directs the Duke-Margolis Institute for Health Policy.
Founding Chair of Computational Medicine and Director of the Center for AI Research and Education at Cedars-Sinai. Former founding Director of the Institute of Biomedical Informatics at the University of Pennsylvania.
We're a team of builders on a mission to transform how medicine advances. Mission-driven, fast-moving, and backed by world-class investors. If hard problems energize you, we'd love to meet you.
